Atropisomerism in the pharmaceutically relevant realm
M Basilaia, MH Chen, J Secka… - Accounts of Chemical …, 2022 - ACS Publications
Conspectus Atropisomerism is a conformational chirality that occurs when there is hindered
rotation about a σ-bond. While atropisomerism is exemplified by biaryls, it is observed in …
rotation about a σ-bond. While atropisomerism is exemplified by biaryls, it is observed in …
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …
decades ago, and activating RET rearrangements and mutations have since been identified …
RET rearrangements are actionable alterations in breast cancer
BS Paratala, JH Chung, CB Williams, B Yilmazel… - Nature …, 2018 - nature.com
Fusions involving the oncogenic gene RET have been observed in thyroid and lung
cancers. Here we report RET gene alterations, including amplification, missense mutations …
cancers. Here we report RET gene alterations, including amplification, missense mutations …
RET signaling in breast cancer therapeutic resistance and metastasis
RET, a single-pass receptor tyrosine kinase encoded on human chromosome 10, is well
known to the field of developmental biology for its role in the ontogenesis of the central and …
known to the field of developmental biology for its role in the ontogenesis of the central and …
[HTML][HTML] Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives
Neoadjuvant endocrine treatment (NET) associates to satisfactory rates of breast
conservative surgery and conversions from inoperable to operable hormone receptor …
conservative surgery and conversions from inoperable to operable hormone receptor …
CATCH: a prospective precision oncology trial in metastatic breast cancer
M Hlevnjak, M Schulze, S Elgaafary, C Fremd… - JCO precision …, 2021 - ascopubs.org
PURPOSE CATCH (Comprehensive Assessment of clinical feaTures and biomarkers to
identify patients with advanced or metastatic breast Cancer for marker driven trials in …
identify patients with advanced or metastatic breast Cancer for marker driven trials in …
Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells
TC Fan, HL Yeo, HM Hsu, JC Yu, MY Ho, WD Lin… - Cancer letters, 2018 - Elsevier
GFRA1 and RET are overexpressed in estrogen receptor (ER)-positive breast cancers.
Binding of GDNF to GFRA1 triggers RET signaling leading to ER phosphorylation and …
Binding of GDNF to GFRA1 triggers RET signaling leading to ER phosphorylation and …
High expression of the RET receptor tyrosine kinase and its ligand GDNF identifies a high-risk subset of estrogen receptor positive breast cancer
RT Kakati, H Kim, A Whitman… - Breast cancer research and …, 2023 - Springer
Purpose Resistance to endocrine therapy is the primary cause of treatment failure and death
in patients with ER-positive (ER+)/luminal breast cancer. Expression and activation of the …
in patients with ER-positive (ER+)/luminal breast cancer. Expression and activation of the …
Targeting the extra-cellular matrix—tumor cell crosstalk for anti-cancer therapy: emerging alternatives to integrin inhibitors
G Lorusso, C Rüegg, F Kuonen - Frontiers in oncology, 2020 - frontiersin.org
The extracellular matrix (ECM) is a complex network composed of a multitude of different
macromolecules. ECM components typically provide a supportive structure to the tissue and …
macromolecules. ECM components typically provide a supportive structure to the tissue and …